Controversies about glucocorticoid for prevention and treatment of bronchopulmonary dysplasia in premature infants
10.3760/cma.j.issn.1673-4912.2022.06.005
- VernacularTitle:糖皮质激素防治早产儿支气管肺发育不良的争议
- Author:
Siyu LIU
1
;
Jiang DUAN
Author Information
1. 昆明医科大学第一附属医院儿科 650032
- Keywords:
Bronchopulmonary dysplasia;
Glucocorticoid;
Inflammation;
Premature infants
- From:
Chinese Pediatric Emergency Medicine
2022;29(6):423-427
- CountryChina
- Language:Chinese
-
Abstract:
Bronchopulmonary dysplasia(BPD) is an important cause of premature infant mortality and long-term organ dysfunction in survivors.There is currently no fundamental treatment for BPD, and glucocorticoids are often used clinically to reduce the risk and severity of BPD.There are systemic administration, inhalation administration and transtracheal administration of glucocorticoids for the prevention and treatment of BPD.Glucocorticoids provide benefits such as anti-inflammatory, but may also cause side effects such as neurodevelopmental impairment.There are various schemes for the dosage form, timing of administration, and cumulative dose of glucocorticoids administration.The clinical advantages and disadvantages of different schemes are inconsistent and controversial.Higher quality clinical trials are needed to provide evidence to support the use of glucocorticoids for the prevention and treatment of BPD.
